ACHIEVE LIFE SCIENCES INC (ACHV) Stock Overview
NASDAQ:ACHV - US0044685008 - Common Stock
ACHV Key Statistics, Chart & Performance
The current stock price of ACHV is 2.98 USD. In the past month the price increased by 16.86%. In the past year, price decreased by -32.12%.
ACHV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About ACHV
Company Profile
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 25 full-time employees. The firm focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. The company has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
Company Info
ACHIEVE LIFE SCIENCES INC
22722 29Th Dr. Se, Suite 100
Seattle WASHINGTON V6E 4H1 US
CEO: John Bencich
Employees: 25
Phone: 14256861500
ACHIEVE LIFE SCIENCES INC / ACHV FAQ
What is the stock price of ACHIEVE LIFE SCIENCES INC today?
The current stock price of ACHV is 2.98 USD. The price decreased by -5.7% in the last trading session.
What is the ticker symbol for ACHIEVE LIFE SCIENCES INC stock?
The exchange symbol of ACHIEVE LIFE SCIENCES INC is ACHV and it is listed on the Nasdaq exchange.
On which exchange is ACHV stock listed?
ACHV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACHIEVE LIFE SCIENCES INC stock?
12 analysts have analysed ACHV and the average price target is 16.32 USD. This implies a price increase of 447.65% is expected in the next year compared to the current price of 2.98. Check the ACHIEVE LIFE SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACHIEVE LIFE SCIENCES INC worth?
ACHIEVE LIFE SCIENCES INC (ACHV) has a market capitalization of 152.28M USD. This makes ACHV a Micro Cap stock.
How many employees does ACHIEVE LIFE SCIENCES INC have?
ACHIEVE LIFE SCIENCES INC (ACHV) currently has 25 employees.
What are the support and resistance levels for ACHIEVE LIFE SCIENCES INC (ACHV) stock?
ACHIEVE LIFE SCIENCES INC (ACHV) has a support level at 2.75 and a resistance level at 2.99. Check the full technical report for a detailed analysis of ACHV support and resistance levels.
Should I buy ACHIEVE LIFE SCIENCES INC (ACHV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACHV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACHV, evaluating the profitability, health, valuation and growth aspects
- ACHIEVE LIFE SCIENCES INC (ACHV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACHIEVE LIFE SCIENCES INC (ACHV) Sales and EPS estimates to see what analysts future expectations are.
- ACHIEVE LIFE SCIENCES INC (ACHV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACHIEVE LIFE SCIENCES INC (ACHV) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACHIEVE LIFE SCIENCES INC (ACHV) Stock Chart to make your own analysis
- ACHIEVE LIFE SCIENCES INC (ACHV) Latest news and press-releases to stay up to date.
Does ACHIEVE LIFE SCIENCES INC (ACHV) stock pay dividends?
ACHV does not pay a dividend.
When does ACHIEVE LIFE SCIENCES INC (ACHV) report earnings?
ACHIEVE LIFE SCIENCES INC (ACHV) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of ACHIEVE LIFE SCIENCES INC (ACHV)?
ACHIEVE LIFE SCIENCES INC (ACHV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.46).
What is the Short Interest ratio of ACHIEVE LIFE SCIENCES INC (ACHV) stock?
The outstanding short interest for ACHIEVE LIFE SCIENCES INC (ACHV) is 5.83% of its float. Check the ownership tab for more information on the ACHV short interest.
ACHV Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ACHV. When comparing the yearly performance of all stocks, ACHV is a bad performer in the overall market: 91.41% of all stocks are doing better.
ACHV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACHV. ACHV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ACHV Financial Highlights
Over the last trailing twelve months ACHV reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by -31.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.55% | ||
| ROE | -121% | ||
| Debt/Equity | 0.21 |
ACHV Forecast & Estimates
12 analysts have analysed ACHV and the average price target is 16.32 USD. This implies a price increase of 447.65% is expected in the next year compared to the current price of 2.98.